Saghi Ghaffari, MD, PhD
- PROFESSOR | Cell, Developmental & Regenerative Biology
Research Topics:
Blood, Cancer, Cell Transformation, Hematopoiesis, Leukemia, Metabolism, Oxidative Stress, Stem Cellshttps://labs.icahn.mssm.edu/ghaffarilab
Saghi Ghaffari MD-PhD is a Professor in Cell, Developmental and Regenerative Biology and a member of Black Family Stem Cell Institute and Tisch Cancer Institute. Dr. Ghaffari is a stem cell biologist with expertise in blood and blood disorders. She was trained in medicine in Paris, France, before obtaining her PhD in Vancouver, Canada. She was a clinical scientist at the Whitehead Institute for Biomedical Research at MIT in Cambridge, MA, after which she joined the faculty of the Icahn School of Medicine at Mount Sinai.
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Development, Regeneration, and Stem Cells [DRS]Education
MD, Universite de Paris XII, Paris, France
Clinical Scientist, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology
MSc, Universite de Paris XII, Paris, France
PhD, University of British Columbia, Vancouver, B.C., Canada
-
2015
American Society of Hematology Bridge Grant Award -
2011
Myeloproliferative Neoplam (MPN) Foundation -
2008
Roche Foundation for Anemia Research (RoFAR) Award -
2008
Irma Hirschl/Weill-Caulier Trust Research Award -
1998
NIH Clinician Scientist Career Award -
1998
Research Scholar -
1991
National Cancer Institute of Canada
Blood, Blood Disorders and Stem Cells
The Ghaffari lab works on exposing mechanisms that maintain healthy blood stem and progenitor cell production throughout life that may be perturbed in blood disorders. The ultimate goal of the lab is to explore these mechanisms for therapy by improving blood production and interfering with disease. The topics of interest in the laboratory are blood forming (hematopoietic) stem cells, their alterations with aging and in myeloid malignancies as well as maturation of red blood cells and their alterations in disease. We are particularly focused on metabolic programs regulated through organelles outside of the nucleus that impact blood production. This approach has been fruitful in identifying new players that are promising in their potential to improve therapy. In carrying our work forward, we have set up multiple collaborations with investigators at Mount Sinai and elsewhere. Several projects derived from our work are available to PhD and MD/PhD students at Mount Sinai.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Ghaffari during 2019 and/or 2020. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Rubius Therapeutics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.